Manufacturer:
Gilead
Route of Administration:
Oral
Site of Care:
Outpatient
Website:
Approved Indication:
treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis, with compensated cirrhosis, or with decompensated cirrhosis for use in combination with ribavirin
Conditions:
- Chronic Viral Hepatitis C
Therapeutic Area:
- Gastroenterology
- Hepatology
- Infectious Disease